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Poster Session II S331Results: Liver stiffness was significantly correlated with thalassemia
classification (p 5 0.001), iron deposition (p 5 0.003) and fibrosis
stage (p\0.001).MedianTE values were significantly different in pa-
tients with severe fibrosis (stage 3-5) 4.5 (60.8 SD) kPa from those
with mild or no fibrosis (stage 0-2) 3.9 (62.8 SD) kPa (p 5 0.000).
The AUROC for prediction of high fibrosis stages (3-5) was 0.802
(95% confidence interval [CI]: 0.665-0.938) with cut-off of 4.35
kPa with 81.8% sensitivity (95% CI: 52.3-94.9) and 70.0% specific-
ity (95% CI: 52.1-83.3).
Conclusion: Our results demonstrate that transient elastography is
a reliable non-invasive tool to evaluate liver iron content and fibrosis
in patients with b-thalassemia major who are candidates for hemato-
poietic stem cell transplantation and can be an alternative to liver bi-
opsy. Moreover, it is a valuable tool to follow-up the liver status in
patients with b-thalassemia major after transplantation.342
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR SECOND-
ARY ACUTE MYELOID LEUKEMIA EVOLVING FROM MYELODYSPLASTIC
SYNDROME
Park, Y.-H., Lee, J.-H., Lee, K.-H., Kim, D.-Y., Kim, S.-D., Choi, Y.,
Seol,M., Lee, Y.-S., Kang, Y.-A., Jeon,M., Lee, J.-H. AsanMedical Cen-
ter, Seoul, Korea
Background: Secondary acute myeloid leukemia (AML) evolving
from myelodysplastic syndrome (MDS) is associated with a poor
prognosis and long-term survival is expected in only a small propor-
tion without allogeneic hematopoietic cell transplantation (HCT).
Methods:Weevaluated clinical outcomes of 37 consecutive patients
who underwent allogeneic HCT for secondary AML evolving from
MDS between January 1997 and April 2010 in a single institute. We
also tried to identify prognostic factors for the outcomes.
Results:Median age of the patients, 22 males and 15 females, was 46
years (range, 25-70). Median duration from diagnosis of MDS to
AML evolution was 2.8 months (range, 0.2-31.0). Before evolution
to AML, MDS was treated with hypomethylating agents in 11 pa-
tients, intensive chemotherapy in 1, and supportive care only in 25.
Twenty-six patients received induction chemotherapy for AML evo-
lution and 14 of them (54%) attained complete remission (CR). All
patients were well engrafted at a median day 15 (range, 6-39).
Nine of 37 patients (24.3%) developed acute GVHD and 13 of 26
assessable patients (50.0%) developed chronic GVHD. After a me-
dian follow-up duration of 38.0 months (range, 4-164), 18 patients
died of disease progression or recurrence (n 5 10) or non-relapse
causes (n 5 8). The 3-year probabilities of overall survival (OS), re-
lapse-free survival (RFS), and non-relapse mortality (NRM) were
47%, 65%, and 24%, respectively. Multivariate analyses revealed
that female sex (vs. male; HR, 4.6; p5 0.006), reduced-intensity con-
ditioning regimen (vs. myeloablative; HR, 4.0; p5 0.030), and hypo-
methylating therapy or intensive chemotherapy for MDS (vs.
supportive care only; HR, 3.7; p5 0.012) were independently unfa-
vorable prognostic factors for OS; shorter duration (\ 4 months)
from AML evolution to HCT (vs. $ 4 months; HR, 0.245; p 5
0.047) and reduced-intensity conditioning regimen (vs. myeloabla-
tive; HR, 6.1; p 5 0.040) were unfavorable prognostic factors for
RFS; there was no independent prognostic factor for NRM. Patients
who developed acute GVHD showed a trend for superior RFS (p 5
0.058), but inferior NRM (p 5 0.127). Patients who developed
chronic GVHD had higher OS (p 5 0.006) and RFS (p 5 0.031).
Conclusions: Allogeneic HCT was an effective therapy for second-
ary AML evolving fromMDS. Clinical outcomes were inferior with
reduced-intensity conditioning than myeloablative conditioning.
Presence of graft-versus-leukemia effects was evident.343
PERIPHERAL BLOOD PROGENITOR CELL (PBPC) TRANSPLANTATION
FROM HAPLOIDENTICAL DONORS FOLLOWING REDUCED INTENSITY
CONDITIONING (RIC) FOR HIGH-RISK HEMATOLOGIC MALIGNANCIES
Raj, K.1, Streetly, M.1, Kazmi, M.1, Harringon, E.2, Getzendaner, L.C.2,
Lee, S.J.2,3, O’Donnell, P.V.2,3 1Guy’s and St. Thomas Hospital, King’sHealth Partners, London, United Kingdom; 2Fred Hutchinson Cancer Re-
search Center/Seattle Cancer Care Alliance, Seattle, WA; 3University of
Washington, Seattle, WA
Donor availability can be a significant obstacle to allogeneic
blood or marrow transplantation (BMT). Single- and multi-center
studies have shown that partially HLA-mismatched (haploidentical)
bone marrow from family members is a suitable source of donor
cells, thus extending this potentially curative treatment to patients
who lack HLA-matched donors. Use of PBPC instead of marrow
for haploidentical transplantation may allow wider applicability of
this approach but there is concern about risk of acute and chronic
GvHD due to the 5-10-fold higher number of T-cells in the
allograft.
We report preliminary results on 14 patients with HL or NHL
and 4 patients with MDS or leukemia (median age 51 yr) who re-
ceived allogeneic transplantation of T-replete PBPC from haploi-
dentical donors at our two centers. We used the protocol
reported by Brunstein, et al. (Blood 118:282 [2011]) except that
PBPC were substituted for bone marrow as the graft source. RIC
consisted of 30 mg/m2/d of fludarabine on days -6 to -2, 14.5
mg/kg/d of cyclophosphamide on days -6 and -5 and 200 cGy
TBI on day -1. PBPC were mobilized and collected in the standard
manner. GvHD prophylaxis included post-transplant cyclophos-
phamide (50 mg/kg/d on days +3 and +4) followed on day +5 by
standard dosing of tacrolimus and mycophenolate. The median
number of HLA-mismatches in the HvG and GvH directions
were 5 and 4, respectively. Allografts contained a median of 6 x
106 CD34 cells/kg and 18 x 107 CD3 cells/kg. Median times to
neutrophil and platelet recovery were 16 and 17 d, respectively.
One patient (6%) rejected their graft and recovered autologous he-
matopoiesis. All other recipients were 100% donor chimeras by day
+28. Grade II acute GvHD was observed in 11 of 16 (69%) evalu-
able patients and Grade III GvHD was observed in one patient
(6%). No chronic GvHD by NIH criteria was observed in patients
who survived beyond day +100. Three of 18 (16%) patients died of
non-relapse causes, all due to infection. Median follow-up of sur-
viving patients is short. Six patients have relapsed (4 of 14 lympho-
mas including 3 patients with ATLL and 1 of 4 patients with
myeloid malignancies). Our results suggest that PBPC can be
substituted for marrow as the donor source in haploidentical trans-
plantation with low rates of rejection, acute and chronic GvHD and
NRM that are similar to those observed after transplantation of
haploidentical bone marrow using this protocol.344
CHIMERISM TESTINGWITH REDUCED INTENSITY INTRAVENOUS BUSUL-
FAN-BASED CONDITIONING REGIMENS: ONCE IS ENOUGH
Bredeson, C.1, Burkart, J.2, Zhu, X.2, Sun, Y.3, LeRademacher, J.2,
Pasquini,M.2, Armstrong, E.3, Rizzo, J.D.2, Kato, K.3 1The OttawaHos-
pital, Ottawa, ON, Canada; 2CIBMTR, Medical College of Wisconsin,
Milwaukee, WI; 3Otsuka Pharmaceutical Development and Commercial-
ization Inc., Princeton, NJ
The CIBMTR is conducting a non-inferiority study of IV busul-
fan-based conditioning regimens vs. traditional ablative cyclophos-
phamide and TBI in patients (pts) with myeloid malignancies
undergoing related or unrelated SCT. Of 1750 pts, we describe
the practices and outcomes of chimerism testing in 155 pts who re-
ceived RIC in this study. 7 had no chimerism testing; data is avail-
able on 140 pts. A total of 807 chimerism assays were performed.
Initial chimerism testing was most commonly performed at day
30 (95/140pts) while only a small percentage had their first chime-
rism ./ 5 90 days post-SCT (19/140pts). Chimerism testing was
performed at a median of 3 (1-6) time points with a median of 5
(1-24) separate assays per patient. Multiple cell types (at least 3
types) were assayed (e.g. BM +/- PB MNC +/- lymphocytes +/- lin-
eage specific cells) in 45 pts, often at one time point. Other com-
mon patterns of testing in a single episode of care were BM +
PBMC (n32), PBMC only (n23), PB T and B cells (n18), BM
only (n13) and other combinations (n9). In 62 instances chimerism
was performed on the BM and PB at the same time. BM chimerism
differed by \10% from PBMC in 21, myeloid cells in 15 and T
S332 Poster Session IIcells in 15 assays. BM chimerism was at least 10% lower than PB,
M or T cell chimerism in 9/62 assays while PB chimerism was at
least 10% lower than BM chimerism twice. Engraftment (.90%
donor chimerism) occurred in at least one cell line in 124 of 140
pts. The vast majority of pts achieved this by day 60 post-SCT.
28 pts subsequently lost full chimerism; 25 in association with dis-
ease (dx) progression, 3 without progression. 33 pts had dx progres-
sion and/or died without losing full donor chimerism. 3 pts
achieved only myeloid donor chimerism; all are alive without dx
progression. 4 pts had testing but did not report results. With a me-
dian follow up of 12 mos, 85 pts are alive, 56 without dx progres-
sion and with full donor chimerism. Chimerism is commonly
performed following RIC regimens but practices vary widely even
within centers and individual pts. Although loss of donor chime-
rism is most commonly related to dx progression, maintenance of
chimerism does not exclude dx progression, bringing into question
the role of serial monitoring. Outside of a research protocol, for pts
receiving IV busulfan-based RIC, chimerism at a single time point
(d60) to confirm engraftment with no further routine testing
would be cost effective.Table 1. Patient Characteristics
Characteristics All FLT3/ITD 2 FLT3/ITD +
Patients: (n 5 ) 75 59 (78.7%) 16 (21.3%)
Age: (median in years) 49 47.9 50.6
Gender:
Female: 38 (50.7%) 30 8
Male: 37 (49.3%) 29 8
WBC at diagnosis: (median) 15 30.9 34.0
Karyotype:
Normal: 36 (48%) 24 12
Abnormal: 37 (49.3%) 33 4
Unknown: 2 (2.6%) 2 0
Conditioning Regimen:
Myeloablative: 42 (56%) 31 11
Reduced Intensity Conditioning: 33 (44%) 28 5
Donor Type:
Matched Related: 35 (46.7%) 29 6
Matched Unrelated: 29 (38.7%) 24 5
Umbilical Cord: 7 (9.3%) 4 3
Haploidentical: 4 (5.3%) 2 2
Stem Cell Source:
PBSCT: 55 (73.3%) 45 10
Bone Marrow: 13 (17.4%) 10 3
Umbilical Cord: 7 (9.3%) 4 3
GVHD prophylaxis:
CSA/MTX: 39 (52%) 31 8
CSA/MMF: 25 (33.3%) 22 3
FK/MMF: 8 (10.7%) 5 3
Other: 3 (4%) 1 2
Use of Thymoglobulin:
Yes: 18 (24%) 13 5
No: 57 (76%) 46 11
Graft Failure:
Yes: 2 (2.5%) 1 1
No: 73 (97.5%) 58 15
Relapsed:
Yes: 21 (28%) 13 (22%) 8 (50%)
No: 54 (72%) 46 (78%) 8 (50%)
Alive:
Yes: 45 (60%) 35 (59.3%) 10 (63%)
No: 30 (40%) 24 (40.7%) 6 (37%)
Abbreviations: CSA indicates cyclosporine; MTX, methotrexate; MMF,
Mycofenolate Mofetil; FK, FK 507; PBSCT, peripheral blood stem cell
transplant.345
USE OF CYCLOSPORINE IS ASSOCIATEDWITH THE INCREASE IN PRE-EN-
GRAFTMENT SYNDROME AFTER MYELOABLATIVE DUAL CORD BLOOD
TRANSPLANTATION
Kanda, J.1, Kaynar, L.1, Kanda, Y.2, Prasad, V.K.3, Parikh, S.H.3,
Rizzieri, D.A.1, Long, G.D.1, Sullivan, K.M.1, Gasparetto, C.1,
Chute, J.P.1, Morris, A.1, Winkel, S.1, McPherson, J.1, Kurtzberg, J.3,
Chao, N.J.1, Horwitz, M.E.1 1Duke University Medical Center,
Durham, NC; 2Saitama Medical Center, Jichi Medical University,
Saitama, Japan; 3Duke University Medical Center, Durham, NC
Background: High fever and/or rash prior to neutrophil engraft-
ment is frequently observed after umbilical cord blood transplanta-
tion (UCBT) and is called pre-engraftment syndrome (PES). Few
studies have evaluated risk factors and treatment response for PES.
Therefore, we retrospectively characterized PES in 57 consecutive
engrafted patients (. 5 12 years old) who received myeloablative
dual UCBT.
Methods: Patients received 2 UCB grafts that were at least 4 of 6
HLA-matched with the recipient. All patients received TBI (. 5
13.2Gy)-based myeloablative conditioning. Tacrolimus (Tac)
(n 5 35) or cyclosporine (CyA) (n 5 22) combined with mycophe-
nolate mofetil was used as a GVHD prophylaxis. CyA was more
commonly used in patients receiving a more intensive conditioning
regimen containing cyclophosphamide. PES was defined as the
presence of either non-infectious fever (. 5 38.5C) and/or rash
prior to or on the day of neutrophil engraftment. The incidence
of PES and overall survival (OS) rate was estimated using the Ka-
plan-Meier method. Incidence of acute GVHD (aGVHD) was es-
timated using the cumulative incidence method. Factors with
p \0.20 in the univariate analysis were used in the multivariate
model.
Results: Median age of patients was 28 (range 12-58) years. The
median combined total nucleated cell dose was 4.8 (range, 2.8-
10.1) x 107/kg. The incidence (95% CI) of PES, grades II-IV
and III-IV aGVHD were 0.77 (0.63-0.86), 0.60 (0.46-0.71), and
0.32 (0.20-0.44), respectively. Multivariate analysis showed that
the use of CyA was the only significant variable associated with
PES (CyA vs. Tac; HR 3.25, p 5 0.003). The use of CyA was
also a significant variable for grade III-IV aGVHD (HR 3.02,
p 5 0.020). Twenty-four of 44 patients with PES were treated
with . 5 1 mg/kg of methylprednisolone or prednisone, which re-
sulted in complete and partial response at day 7 in 10 and 14 pa-
tients, respectively. Acute GVHD developed in 7 of 20 patients
who did not receive systemic treatment for PES (grades II in 3
and grades III-IV aGVHD in 4). Although OS in the Tac group
tended to be higher than in the CyA group, there was no statistical
difference between the two group (p 5 0.102).
Conclusion:GVHD prophylaxis with CyA vs. Tac was a risk factor
for both PES and grades III-IV aGVHD after myeloablative dual
UCBT in our cohort. The impact of GVHD prophylaxis (CyA vs.
Tac) in UCBT will need to be confirmed in a prospective trial
with a uniform conditioning regimen.346
ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3/ITD POSITIVE
ACUTE MYELOID LEUKEMIA IN CR1: IMPLICATION FOR PERSONALIZED
THERAPY TO PREVENT EARLY RELAPSES
Sengsayadeth, S.M.1, Jagasia, M.1, Engelhardt, B.G.1, Kassim, A.1,
Strickland, S.A.1, Goodman, S.1, Lucid, C.1, Vnencek-Jones, C.L.2,
Greer, J.P.1, Savani, B.N.1 1Vanderbilt University Medical Center,
Nashville, TN; 2Vanderbilt University Medical Center, Nashville, TN
Objective: Fms-Like Tyrosine kinase 3/Internal Tandem Duplica-
tion (FLT3/ITD) mutation in patients with acute myeloid leukemia
(AML) is associated with shorter disease free survival (DFS) and
overall survival (OS). Although evidence from prospective trials is
lacking, allogeneic stem cell transplantation (allo-SCT) is often con-
sidered in patients with FLT3/ITD+ AML in first complete remis-
sion (CR1). Prognostic significance of FLT3/ITD mutation
compared to other conventional prognostic markers in patients re-
ceiving allo-SCT in AML-CR1 is unknown.
Methods: 79 consecutive patients with AML in CR1 received allo-
SCT between June 2005 and May 2011 at Vanderbilt University
Medical Center. 4 patients with unknown FLT3/ITD status were
excluded. The prognostic impact of FLT3/ITD mutation was eval-
uated in the context of other clinical prognostic and genetic risk fac-
tors.
Results: FLT3/ITDmutation was present in 16 (21%) of the 75 pa-
tients who underwent allo-SCT in CR1. There were no significant
differences in age, WBC at diagnosis, or transplant characteristics
